Background
==========

Gastric cancer (GC) is the fourth most common malignancy and is the third leading cause of cancer-associated mortality worldwide \[[@b1-medscimonit-24-8524]\]. Signet-ring cell carcinoma (SRC) is a histological subtype of adenocarcinoma, with cells containing high levels of intracytoplasmic mucins \[[@b2-medscimonit-24-8524]\]. SRC is seen most commonly in the stomach (95%) and occasionally in the colon, rectum, ovary, breast, and gallbladder. Approximately 15--28% of GCs are SRCs \[[@b3-medscimonit-24-8524],[@b4-medscimonit-24-8524]\]. SRC of the stomach was classified as an undifferentiated type according to the Japanese Gastric Cancer Association \[[@b5-medscimonit-24-8524]\].

Age at diagnosis is an indispensable adjusted element in observational studies, as well as a promising prognostic factor for survival in multiple cancers \[[@b6-medscimonit-24-8524]--[@b8-medscimonit-24-8524]\]. In GC, the data are conflicting regarding survival outcomes among younger patients. For example, Wang et al. reported overall 5-year survival rates in younger and older groups of 60.8% and 53.7%, respectively (*P*=0.017). When stratified by TNM stage, the younger group at stage IV exhibited better 5-year survival compared with the older group (26.9% *vs.* 10.3%, *P*=0.003) \[[@b9-medscimonit-24-8524]\]. Kim et al. \[[@b10-medscimonit-24-8524]\] reported overall 5-year survival rates in younger and older groups of 84.3% and 89.6%, respectively (*P*=0.172), while another study found that the 5-year survival rates did not differ significantly between younger (≤45 years) and older (\>45 years) GC patients (69.97% *vs.* 69.03%, *P*=0.534). However, in curatively resected patients, the 5-year survival rate was significantly better in the younger group (80.81% *vs.* 75.42%; *P*=0.002) \[[@b11-medscimonit-24-8524]\].

GC patients with SRC tend to be younger than non-SRC patients \[[@b12-medscimonit-24-8524],[@b13-medscimonit-24-8524]\]. Some studies investigated the effect of age on the survival of patients with gastric SRC. Yokota et al. \[[@b14-medscimonit-24-8524]\] carried out a retrospective analysis of 93 patients with SRC of the stomach who were operated on between 1985 and 1995. They reviewed the clinicopathologic characteristics and found that vascular invasion and tumor location were statistically significant prognostic factors, whereas age, tumor size, and lymph node metastasis were not. Jiang et al. used multivariate Cox regression analysis to demonstrate that sex, age, lymph node metastatic ratio, pTNM stage, curative operation, and distant metastasis were independent prognostic factors; in addition, a younger age predicted worse cancer-specific survival (CSS) \[[@b15-medscimonit-24-8524]\]. Moreover, using multivariate analysis, Liu et al. \[[@b16-medscimonit-24-8524]\] found higher 5-year overall survival rates in younger than in older patients with gastric SRC. Therefore, the effects of younger age on the prognosis of gastric SRC are controversial, and these studies have been generally limited by small numbers of patients and a limited ability to assess CSS accurately.

To perform a comprehensive analysis of gastric SRC, we used data from the Surveillance, Epidemiology, and End Results (SEER) database to investigate the impact of age on clinicopathological features and identify independent prognostic factors for gastric SRC using a multivariate approach.

Material and Methods
====================

Patient selection
-----------------

The SEER database is a population-based cancer registry containing data from 18 sites that cover approximately 30% of the United States population \[[@b17-medscimonit-24-8524]\]. We used SEER Stat software (Surveillance Research Program, National Cancer Institute SEER Stat software, *[www.seer.cancer.gov/seerstat](www.seer.cancer.gov/seerstat)*, version 8.3.4) to identify patients who were diagnosed with gastric SRC. Data regarding age, sex, race, marital status, histological type, American Joint Committee on Cancer (AJCC) stage, tumor site, number of positive lymph nodes, and gastric CSS were extracted from the SEER database for further analysis.

Inclusion and exclusion criteria
--------------------------------

The inclusion criteria were as follows: the tumor site was limited to the stomach (C16.0--16.9), which was further categorized as the proximal third (cardia and fundus), mid-third (body and lesser curvature), distal third (antrum and pylorus), greater curvature, and overlapping lesions of the stomach; histological type was limited to SRC (ICD-03, 8490/3); diagnosis was made between 2004 and 2012; and the diagnostic confirmation method was limited to microscopic. The exclusion criteria were incomplete patient information regarding sex, race, marital status, histological type, AJCC stage, tumor site, number of positive lymph nodes, or survival time. The timeframe of 2004--2012 was selected because AJCC TNM staging became available in 2004, and patients diagnosed after 2012 were excluded to ensure an adequate follow-up time. Cases diagnosed before 2010 were restaged according to the criteria described in the 7th edition of the AJCC staging manual (2010).

Statistical analysis
--------------------

The study endpoint was gastric CSS, which was calculated from the date of diagnosis to the date of GC-specific death. Deaths caused by GC were treated as events; surviving patients at the last follow-up or deaths from other causes were treated as censored observations. To investigate the impact of age on the prognosis of gastric SRC, age was classified into a categorical variable consisting of 3 groups: \<45, 45--74, and \>74 years. Patient demographics and tumor factors were compared among the age groups using the chi-square test to evaluate proportions. CSS was assessed using the Kaplan-Meier method. Univariate differences among groups were analyzed using log-rank tests, and the significant variables (*P*\<0.05) were further analyzed using a Cox regression model. Multivariate Cox regression models were used to evaluate risk factors for survival outcomes in GC patients. All statistical analyses were performed using Statistical Package for Social Sciences for Mac IOS, version 24 (SPSS Inc., Chicago, IL, USA). A 2-sided *P* value of \<0.05 was considered statistically significant.

Results
=======

Demographic and baseline characteristics of SRC patients
--------------------------------------------------------

A total of 4596 patients with gastric SRC were identified in the SEER database during the 9-year study period (2004--2012). Of these, 625 (13.6%), 2532 (55.1%), and 1439 (31.3%) were aged \<45, 45--74, and \>74 years, respectively. The median follow-up time was 16 months (interquartile range \[IQR\], 7--39.5 months) in the \<45-year-old group, 17 months (IQR, 6--41 months) in the 45--74-year-old group, and 10 months (IQR, 3--29 months) in the \>74-year-old group. Female patients accounted for a greater proportion (55.7%) of the \<45-year-old group, while there was a male predominance in those aged 45--74 years (56.5%). The most common ethnicity was white in all groups ([Table 1](#t1-medscimonit-24-8524){ref-type="table"}).

The distal third gastric region was the most frequent primary tumor location in each age group of GC patients. No differences in the grade of differentiation or number of positive lymph nodes harvested were found among the age groups. The \<45-year-old group had significantly higher proportions of patients with AJCC T4, N2, and M1 stages compared with the other 2 groups (*P*\<0.001 for all); thus, these patients presented with a more advanced AJCC clinical stage (IV, *P*\<0.001). However, the \<45-year-old group had fewer patients with stage I, II, or III disease compared with the other 2 groups (*P*\<0.001 for all). There were no significant differences in tumor size among the groups (*P*=0.093; [Table 1](#t1-medscimonit-24-8524){ref-type="table"}).

Impact of age on CSS in SRC patients
------------------------------------

The 5-year CSS was 36.3% in patients aged \<45 years, 35.74% in patients aged 45--74 years, and 31.83% in patients aged \>74 years, suggesting that survival outcomes were more favorable among the youngest age group of patients ([Figure 1](#f1-medscimonit-24-8524){ref-type="fig"}; [Table 2](#t2-medscimonit-24-8524){ref-type="table"}). Moreover, when CSS was further stratified according to AJCC stage, these observations remained true for all stage strata ([Figure 2](#f2-medscimonit-24-8524){ref-type="fig"}; [Table 3](#t3-medscimonit-24-8524){ref-type="table"}). In univariate survival analyses, grade (*P*=0.016), age, race, tumor size, tumor location, number of positive lymph nodes, AJCC TNM stage, and clinical stage (all *P*\<0.001) were significant risk factors for poor survival ([Table 2](#t2-medscimonit-24-8524){ref-type="table"}).

The multivariate Cox proportional model further demonstrated age to be an independent prognostic factor for CSS. The hazard ratio (HR) increased steadily with age, and the \>74-year-old group had the poorest survival outcome compared with the other 2 age groups (HR, 1.841; 95% confidence interval \[CI\], 1.636--2.071, *P*\<0.001). Five other variables were also independent prognostic factors: ethnicity (using white as a reference; others: HR 0.825, 95% CI 0.746--0.913, *P*\<0.001; unknown: HR 0.435, 95% CI 0.195--0.97, *P*=0.042; there was no significant difference in risk between black and white, *P*=0.173); tumor location (using the proximal third as the reference; mid-third: HR 0.82, 95% CI 0.733--0.916, *P*\<0.001; distal third: HR 0.819, 95% CI 0.738--0.909, *P*\<0.001; greater curvature: HR 0.826, 95% CI 0.689--0.99, *P*=0.038); tumor size (using ≤5 cm as the reference; \>5 cm: HR 1.324, 95% CI 1.198--1.464, *P*\<0.001); positive lymph nodes (using \<15 as the reference; ≥15: HR 1.197, 95% CI 1.067--1.342, *P*=0.002); clinical stage (using stage I as the reference; stage II: HR 1.898, 95% CI 1.644--2.191, *P*\<0.001; stage III: HR 3.237, 95% CI 2.827--3.705, *P*\<0.001; stage IV: HR 6.791, 95% CI 5.921--7.788, *P*\<0.001) ([Table 2](#t2-medscimonit-24-8524){ref-type="table"}).

Discussion
==========

Although the incidence and mortality of GC have decreased in many countries over the past 50 years, the rate of gastric SRC-type cancer has increased sharply. Donald et al. used the SEER database to identify an increase in the incidence of the diffuse type of GC from 0.3 cases per 100 000 persons in 1973 to 1.8 cases per 100 000 persons in 2000, and the predominant increase occurred in the SRC subtype \[[@b18-medscimonit-24-8524]\]. Some other investigators have also reported an obvious increase in the occurrence of SRC subtype GC worldwide \[[@b18-medscimonit-24-8524]--[@b20-medscimonit-24-8524]\]. Furthermore, Postlewaite et al. \[[@b21-medscimonit-24-8524]\] recently found that the SRC subtype was present in 40.6% of 768 gastric adenocarcinoma patients and was associated with a younger age.

Compared with non-signet-ring cell carcinoma, gastric SRC patients have worse outcomes, different prognostic factors, a tendency for metastases, and reduced sensitivity to chemotherapy \[[@b22-medscimonit-24-8524]--[@b25-medscimonit-24-8524]\]. As a subtype of GC associated with poor survival, gastric SRC has an intrinsic genetic basis that is responsible for its high rate of malignancy. It was reported that SRC cells rarely adhere to each other because of downregulated E-cadherin expression, which is important for cell adhesion; therefore, SRC cells are more likely to metastasize \[[@b23-medscimonit-24-8524],[@b26-medscimonit-24-8524]\]. Yang et al. \[[@b27-medscimonit-24-8524]\] revealed that \>80.0% of gastric SRCs express the oestrogen receptor (ER), and SRC cells are prone to metastasize to the ovary or uterine cervix in the presence of high levels of oestrogen. Gastric SRC expresses heparanase (HPA) during the very early stages of progression; high levels of HPA and cyclooxygenase-2 (whose expression is induced by HPA and other factors) stimulate angiogenesis, tumor growth, and tumor invasion. However, the exact genetic mechanism behind young-onset gastric SRC is still largely unknown. Therefore, further comparative studies are needed to delineate the genetic peculiarity of young-onset gastric SRC.

Although several studies have evaluated the prognostic value of various factors in GC, the prognostic determinants of gastric SRC are largely undefined \[[@b28-medscimonit-24-8524]\], and the impact of age on the prognosis of gastric SRC remains controversial. In the current study, a total of 4596 patients with gastric SRC were included to evaluate the impact of age on prognosis. The lowest HR was observed in the younger group (\<45 years), and the risk increased with age and was highest for the older group (\>74 years). Moreover, younger patients with gastric SRC presented with more frequent deep invasion and distant metastasis, which was consistent with other studies. We believe that this could be attributed to the following factors. First, the morbidity of GC is lower among younger patients, and the clinical symptoms of early GC and common benign diseases overlap; therefore, GC in younger people may not be considered at the time of presentation. Second, there has been less incentive to establish surveillance endoscopy programs to identify younger patients at an earlier stage. However, our data showed that the 5-year CSS of the younger group exceeded those of the older cohorts. The worse survival in older patients is in part due to poor tolerance to extensive lymphadenectomy and adjuvant chemotherapy because of a poorer performance status and presence of many more comorbidities compared with younger patients \[[@b29-medscimonit-24-8524]\]. In addition, poorer tolerance to surgical complications and adjuvant treatments and greater difficulty restoring gastrointestinal function may be evident in older patients compared with younger patients \[[@b30-medscimonit-24-8524],[@b31-medscimonit-24-8524]\].

In the present study, Asians, Native Americans, and Pacific Islanders had better prognoses than those of white and black patients. These findings are consistent with previous studies. For example, a study in the United States found that Asians had a better prognosis than those of African Americans, whites, and Hispanics with gastric SRC \[[@b20-medscimonit-24-8524]\]. Gill et al. \[[@b32-medscimonit-24-8524]\] found more favorable outcomes after curative surgery in Asians than in non-Asians with GC. The present study also found that tumor location was associated with CSS, which is consistent with other studies showing a worse prognosis for tumors located in the proximal third compared with the antrum or pylorus \[[@b24-medscimonit-24-8524],[@b32-medscimonit-24-8524]\]. Not surprisingly, tumor size, positive lymph nodes, and clinical stage at diagnosis were powerful independent prognostic factors for gastric SRC. Furthermore, our analyses found no significant association between sex or marital status and CSS. In the univariate analyses, we found that pathological grade was associated with CSS; however, no significant difference was detected in the multivariate analysis, indicating that pathological grade was not an independent prognostic factor.

Although our analysis is convincing because it was a large population-based study, it still has several potential limitations. First, the SEER database lacks important chemotherapy-related information such as the specific chemotherapy regimens used, adjuvant versus neoadjuvant treatment, and the treatment duration. Second, the SEER database does not separate palliative from curative surgeries. Finally, the SEER database does not include information on comorbidities, nutritional status, or family history. Thus, our study could not adjust for these potential confounding factors.

Conclusions
===========

In conclusion, our analysis used the SEER database to demonstrate that younger patients (\<45 years) with gastric SRC presented with more advanced disease. However, their survival outcomes were more favorable than those of the older cohorts, and these observations remained true after stratification by AJCC stage. Clinicians should include age in their assessments and treatment decisions for patients with gastric SRC.

The authors acknowledge the efforts of the SEER Program tumor registries in the creation of the SEER database.

**Source of support:** This study was supported by Shanghai Committee of Science and Technology Funds (NO. 15411960300); Key Medical Specialty funded by the Fifth People's Hospital of Shanghai, Fudan University (NO. 2017WYZDZK01); and Great Discipline Construction Project from the Medical System of Shanghai Minhang District (NO. 2017MWDXK01)

**Conflicts of interest**

None.
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###### 

Characteristics of patients with signet-ring cell carcinoma of the gastric from the SEER database by age at diagnosis.

  Characteristics                                               All patients   \<45 years   45--74 years   \>74 years    P value
  ------------------------------------------------------------- -------------- ------------ -------------- ------------- ---------
  N (%)                                                         4596 (100)     625 (13.6)   2532 (55.1)    1439 (31.3)   
  Median follow-up, months                                      15             16           17             10            
  Sex, n (%)                                                                                                             0
   Male                                                         2422 (52.7)    277 (44.3)   1430 (56.5)    715 (49.7)    
   Female                                                       2174 (47.3)    348 (55.7)   1102 (43.5)    724 (50.3)    
  Race, n (%)                                                                                                            0
   White                                                        3149 (68.5)    403 (64.5)   1694 (66.9)    1052 (73.1)   
   Black                                                        573 (12.5)     108 (17.3)   340 (13.4)     125 (8.7)     
   Others[\*](#tfn1-medscimonit-24-8524){ref-type="table-fn"}   854 (18.6)     110 (17.6)   487 (19.2)     257 (17.9)    
   Unknown                                                      20 (0.4)       4 (0.6)      11 (0.4)       5 (0.3)       
  Marital status                                                                                                         0
   Married                                                      3310 (72.0)    385 (61.6)   1763 (69.6)    1162 (80.8)   
   Unmarried                                                    1125 (24.5)    220 (35.2)   688 (27.2)     217 (15.1)    
   Unknown                                                      161 (3.5)      20 (3.2)     81 (3.2)       60 (4.2)      
  Tumor location                                                                                                         0
   Proximal third                                               924 (20.1)     79 (12.6)    557 (22.0)     288 (20.0)    
   Mid third                                                    994 (21.6)     140 (22.4)   551 (21.8)     303 (21.1)    
   Distal third                                                 1317 (28.7)    186 (29.8)   706 (27.9)     425 (29.5)    
   Greater curvature                                            247 (5.4)      42 (6.7)     133 (5.3)      72 (5.0)      
   Overlapping lesions                                          546 (11.9)     91 (14.6)    289 (11.4)     166 (11.5)    
   Unknown                                                      568 (12.4)     87 (13.9)    296 (11.7)     185 (12.9)    
  Tumor size (cm)                                                                                                        0.093
   ≤5                                                           1576 (34.3)    184 (29.4)   879 (34.7)     513 (35.6)    
   \>5                                                          1436 (31.2)    208 (33.3)   789 (31.2)     439 (30.5)    
   Unknown                                                      1584 (34.5)    233 (37.3)   864 (34.1)     487 (33.8)    
  PLNH                                                                                                                   0.604
   \<15                                                         4148 (90.3)    571 (91.4)   2281 (90.1)    1296 (90.1)   
   ≥15                                                          448 (9.7)      54 (8.6)     251 (9.9)      143 (9.9)     
  Grade                                                                                                                  0.096
   Low                                                          127 (2.8)      11 (1.8)     67 (2.6)       49 (3.4)      
   High                                                         4469 (97.2)    614 (98.2)   2465 (97.4)    1390 (96.6)   
  T-stage                                                                                                                0
   T1                                                           973 (21.2)     109 (17.4)   495 (19.5)     369 (25.6)    
   T2                                                           423 (9.2)      44 (7.0)     237 (9.4)      142 (9.9)     
   T3                                                           1273 (27.7)    180 (28.8)   724 (28.6)     369 (25.6)    
   T4                                                           1927 (41.9)    292 (46.7)   1076 (42.5)    559 (38.8)    
  N-stage                                                                                                                0
   N0                                                           1846 (40.2)    236 (37.8)   950 (37.5)     660 (45.9)    
   N1                                                           1443 (31.4)    201 (32.2)   844 (33.3)     398 (27.7)    
   N2                                                           737 (16.0)     115 (18.4)   421 (16.6)     201 (14.0)    
   N3                                                           570 (12.4)     73 (11.7)    317 (12.5)     180 (12.5)    
  M-stage                                                                                                                0
   M0                                                           3323 (72.3)    380 (60.8)   1807 (71.4)    1136 (78.9)   
   M1                                                           1273 (27.7)    245 (39.2)   725 (28.6)     303 (21.1)    
  AJCC stage                                                                                                             0
   I                                                            933 (20.3)     89 (14.2)    471 (18.6)     373 (25.9)    
   II                                                           889 (19.3)     98 (15.7)    497 (19.6)     294 (20.4)    
   III                                                          1501 (32.7)    193 (30.9)   839 (33.1)     469 (32.6)    
   IV                                                           1273 (27.7)    245 (39.2)   725 (28.6)     303 (21.1)    

Native Americans, Asians, Pacific Islanders.

PLNH -- number of positive lymph nodes harvested; AJCC -- American Joint Committee on Cancer.

###### 

Univariate and multivariate Cox analyses of determinants of cancer-specific survival (CSS) of patients with signet-ring cell gastric carcinoma.

  Variable                                                      No. of patients   5-year GCSS(%)   Univariate   Multivariate                          
  ------------------------------------------------------------- ----------------- ---------------- ------------ -------------- ------- -------------- -------
  Age                                                                                              46.838       0                                     
   \<45                                                         625               36.30%                                       1       Reference      
   45--74                                                       2532              35.74%                                       1.144   1.025--1.276   0.016
   \>74                                                         1439              31.83%                                       1.841   1.636--2.071   0
  Sex                                                                                              0.057        0.811                                 
   Male                                                         2422              34.72%                                                              
   Female                                                       2174              34.45%                                                              
  Race                                                                                             71.23        0                                     
   White                                                        3149              31.53%                                       1                      
   Black                                                        573               33.86%                                       1.08    0.967--1.205   0.173
   Others[\*](#tfn3-medscimonit-24-8524){ref-type="table-fn"}   854               45.55%                                       0.825   0.746--0.913   0
   Unknown                                                      20                70.00%                                       0.435   0.195--0.97    0.042
  Marital status                                                                                   1.263        0.532                                 
   Married                                                      3310              34.29%                                                              
   Unmarried                                                    1125              34.76%                                                              
   Unknown                                                      161               39.75%                                                              
  Tumor location                                                                                   187.904      0                                     
   Proximal third                                               924               25.97%                                       1                      
   Mid third                                                    994               41.65%                                       0.82    0.733--0.916   0
   Distal third                                                 1317              41.91%                                       0.819   0.738--0.909   0
   Greater curvature                                            247               41.70%                                       0.826   0.689--0.99    0.038
   Overlapping lesions                                          546               23.08%                                       0.931   0.824--1.053   0.255
   Unknown                                                      568               27.29%                                       1.037   0.917--1.174   0.563
  Tumor size (cm)                                                                                  688.588      0                                     
   ≤5                                                           1576              55.46%                                       1                      
   \>5                                                          1436              28.20%                                       1.324   1.198--1.464   0
   Unknown                                                      1584              19.63%                                       2.096   1.899--2.314   0
  PLNH                                                                                             84.323       0                                     
   \<15                                                         4148              36.55%                                       1                      
   ≥15                                                          448               16.52%                                       1.197   1.067--1.342   0.002
  Grade                                                                                            5.762        0.016                                 
   Low                                                          127               45.67%                                       1                      
   High                                                         4469              34.28%                                       1.046   0.827--1.323   0.708
  T-stage                                                                                          488.878      0                                     
   T1                                                           973               55.91%                                                              
   T2                                                           423               51.54%                                                              
   T3                                                           1273              34.72%                                                              
   T4                                                           1927              20.03%                                                              
  N-stage                                                                                          127.5        0                                     
   N0                                                           1846              44.47%                                                              
   N1                                                           1443              30.35%                                                              
   N2                                                           737               28.90%                                                              
   N3                                                           570               20.70%                                                              
  M-stage                                                                                          1252.535     0                                     
   M0                                                           3323              44.00%                                                              
   M1                                                           1273              10.05%                                                              
  AJCC stage                                                                                       1578.803     0                                     
   I                                                            933               68.17%                                       1                      
   II                                                           889               47.24%                                       1.898   1.644--2.191   0
   III                                                          1501              27.05%                                       3.237   2.827--3.705   0
   IV                                                           1273              10.05%                                       6.791   5.921--7.788   0

Native Americans, Asians, Pacific Islanders.

PLNH -- number of positive lymph nodes harvested; AJCC -- American Joint Committee on Cancer.

###### 

Univariate analysis of age on gastric cancer-specific survival by disease stage.

  Variable   No. of patients   5-year GCSS(%)   Log-rank test   P
  ---------- ----------------- ---------------- --------------- -------
  Stage 1                                                       
   Age                                          54.738          0
    \<45     89                83.15                            
    45--74   471               74.73                            
    \>74     373               56.3                             
  Stage 2                                                       
   Age                                          8.339           0.015
    \<45     98                48.98                            
    45--74   497               47.69                            
    \>74     294               45.92                            
  Stage 3                                                       
   Age                                          91.76           0
    \<45     193               34.72                            
    45--74   839               29.68                            
    \>74     469               19.19                            
  Stage 4                                                       
   Age                                          32.425          0
    \<45     245               15.51                            
    45--74   725               9.24                             
    \>74     303               7.59                             
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